Top

PharmacoEconomics

Published in:

01-09-2019 | Pneumococcal Vaccination | Systematic Review

Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions

Authors: Marina Treskova, Stefan M. Scholz, Alexander Kuhlmann

Published in: PharmacoEconomics | Issue 9/2019

Abstract

Background

Previous systematic reviews concluded that pneumococcal vaccination in the elderly was cost effective. However, recently published economic evaluations state that it may not be cost effective when children are vaccinated with higher-valent pneumococcal conjugate vaccines. The literature suggests that the outcomes of vaccination in the elderly are strongly influenced by the vaccine effectiveness (VE) against the vaccine-type pneumococcal diseases (PD) and the impact of childhood vaccination on the vaccine-type PD incidence in the elderly, but the extent remains unclear.

Methods

We conducted a systematic literature search of cost-effectiveness studies on vaccination in the elderly in the PubMed database starting from 2006. We included studies that consider the presence of a childhood vaccination with pneumococcal conjugate vaccine (PCV) 10 and PCV13. We focus on methods and assumptions used in modeling VE and epidemiology of PD over time.

Results

Twenty-eight economic evaluations underwent full-text review and data extraction. Thirteen were selected for quality assessment. The studies with a higher quality score provide evidence that vaccinating the elderly with PCV13 is not cost effective, when an ongoing rapid decline in the incidence of PCV13-type PD is modeled. A moderate persistence of PCV13 serotypes, in particular due to PCV10 childhood vaccination, makes vaccination of the elderly with PCV13 more attractive. There is no agreement that combining PCV13 with polysaccharide vaccine PPSV23 is cost effective. PPSV23 is attractive when it is effective against non-invasive PD.

Conclusion

Methodological approaches and assumptions in modeling VE and the indirect effects of childhood vaccination have a major impact on outcomes of decision-analytic models and cost-effectiveness estimates. Considering recently observed trends in the epidemiology of pneumococcal serotypes, there is currently inconclusive evidence regarding the cost effectiveness of pneumococcal vaccination of the elderly due to lack of studies that model key serotypes such as serotype 3 separately from other groups of serotypes.

Available only for authorised users

Tin Tin Htar M, Christopoulou D, Schmitt H-J. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15:419. https://doi.org/10.1186/s12879-015-1147-x.CrossRefPubMedPubMedCentral

Shiri T, Datta S, Madan J, Tsertsvadze A, Royle P, Keeling MJ, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e51–9. https://doi.org/10.1016/S2214-109X(16)30306-0.CrossRefPubMed

Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009;27:4891–904. https://doi.org/10.1016/j.vaccine.2009.05.061.CrossRefPubMed

Dirmesropian S, Wood JG, MacIntyre CR, Newall AT. A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Hum Vaccin Immunother. 2015;11:818–25. https://doi.org/10.1080/21645515.2015.1011954.CrossRefPubMedPubMedCentral

Nishikawa AM, Sartori AMC, Mainardi GM, Freitas AC, Itria A, Novaes HMD, de Soárez PC. Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older. Vaccine. 2018;36:2510–22. https://doi.org/10.1016/j.vaccine.2018.03.070.CrossRefPubMed

Porchia BR, Bonanni P, Bechini A, Bonaccorsi G, Boccalini S. Evaluating the costs and benefits of pneumococcal vaccination in adults. Expert Rev Vaccines. 2017;16:93–107. https://doi.org/10.1080/14760584.2017.1242419.CrossRefPubMed

Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–25. https://doi.org/10.1056/NEJMoa1408544.CrossRefPubMed

Chen C, Beutels P, Newall AT. Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination. Vaccine. 2018;36:2057–60. https://doi.org/10.1016/j.vaccine.2018.03.006.CrossRefPubMed

Chen C, Wood JG, Beutels P, Menzies R, MacIntyre CR, Dirmesropian S, et al. The role of timeliness in the cost-effectiveness of older adult vaccination: a case study of pneumococcal conjugate vaccine in Australia. Vaccine. 2018;36:1265–71. https://doi.org/10.1016/j.vaccine.2018.01.052.CrossRefPubMed

10.

Willem L, Blommaert A, Hanquet G, Thiry N, Bilcke J, Theeten H, et al. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium. Hum Vaccin Immunother. 2018. https://doi.org/10.1080/21645515.2018.1428507.CrossRefPubMedPubMedCentral

11.

Le Polain De Waroux O, Flasche S, Prieto-Merino D, Goldblatt D, Edmunds WJ. The efficacy and duration of protection of pneumococcal conjugate vaccines against nasopharyngeal carriage: a meta-regression model. Pediatr Infect Dis J. 2015;34:858–64. https://doi.org/10.1097/inf.0000000000000717.CrossRefPubMed

12.

Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17:313–21. https://doi.org/10.1016/S1473-3099(17)30049-X.CrossRefPubMed

13.

Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011. Vaccine. 2013;31:5863–71. https://doi.org/10.1016/j.vaccine.2013.09.049.CrossRefPubMed

14.

Gutiérrez Rodríguez MA, Ordobás Gavín MA, García-Comas L, Sanz Moreno JC, Córdoba Deorador E, Lasheras Carbajo MD, Taveira Jiménez JA, Martín Martínez F, Iniesta Fornies D, Arce Arnaez A. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011. 2014. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES2014.19.40.20922. Accessed 24 Oct 2018.

15.

Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30:6802–8. https://doi.org/10.1016/j.vaccine.2012.09.019.CrossRefPubMed

16.

Svensson T, Kättström M, Hammarlund Y, Roth D, Andersson P-O, Svensson M, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine. 2018;36:3701–7. https://doi.org/10.1016/j.vaccine.2018.05.012.CrossRefPubMed

17.

Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis. 2018;67:367–74. https://doi.org/10.1093/cid/ciy129.CrossRefPubMed

18.

Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med. 2013. https://doi.org/10.1101/cshperspect.a010215.CrossRefPubMedPubMedCentral

19.

World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. 2008. http://www.who.int/iris/handle/10665/69981. Accessed 14 Mar 2018.

20.

Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Evidence and value: impact on decisionmaking—the EVIDEM framework and potential applications. BMC Health Serv Res. 2008;8:270. https://doi.org/10.1186/1472-6963-8-270.CrossRefPubMedPubMedCentral

21.

OECD. Inflation (CPI) (indicator): OECD; 2017. https://data.oecd.org/price/inflation-cpi.htm. Accessed 3 Sept 2018.

22.

OECD. Purchasing power parities (PPP) (indicator): OECD; 2017. https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm. Accessed 3 Sept 2018.

23.

OECD. Exchange rates (indicator): OECD; 2017. https://data.oecd.org/conversion/exchange-rates.htm. Accessed 3 Sept 2018.

24.

Jiang Y, Gauthier A, Annemans L, van der Linden M, Nicolas-Spony L, Bresse X. Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany. Expert Rev Pharmacoecon Outcomes Res. 2012;12:645–60. https://doi.org/10.1586/erp.12.54.CrossRefPubMed

25.

Mangen M-JJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46:1407–16. https://doi.org/10.1183/13993003.00325-2015.CrossRefPubMedPubMedCentral

26.

Blommaert A, Bilcke J, Willem L, Verhaegen J, Goossens H, Beutels P. The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: an exploration of influential factors for Belgium. Vaccine. 2016;34:2106–12. https://doi.org/10.1016/j.vaccine.2016.03.003.CrossRefPubMed

27.

Rodriguez Gonzalez-Moro JM, Menendez R, Campins M, Lwoff N, Oyaguez I, Echave M, et al. Cost effectiveness of the 13-valent pneumococcal conjugate vaccination program in chronic obstructive pulmonary disease patients aged 50 + years in Spain. Clin Drug Investig. 2016;36:41–53. https://doi.org/10.1007/s40261-015-0345-z.CrossRefPubMed

28.

Stoecker C, Kim L, Gierke R, Pilishvili T. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States. J Gen Intern Med. 2016;31:901–8. https://doi.org/10.1007/s11606-016-3651-0.CrossRefPubMedPubMedCentral

29.

van Hoek AJ, Miller E. Cost-effectiveness of vaccinating immunocompetent/= 65 year olds with the 13-valent pneumococcal conjugate vaccine in England. PLoS One. 2016;11:e0149540. https://doi.org/10.1371/journal.pone.0149540.CrossRefPubMedPubMedCentral

30.

Dirmesropian S, Wood JG, MacIntyre CR, Beutels P, McIntyre P, Menzies R, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. Vaccine. 2017;35:4307–14. https://doi.org/10.1016/j.vaccine.2017.06.085.CrossRefPubMed

31.

Heo JY, Seo YB, Choi WS, Lee J, Noh JY, Jeong HW, et al. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS One. 2017;12:e0177342. https://doi.org/10.1371/journal.pone.0177342.CrossRefPubMedPubMedCentral

32.

Thorrington D, van Rossum L, Knol M, de Melker H, Rümke H, Hak E, van Hoek AJ. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PLoS One. 2018;13:e0192640. https://doi.org/10.1371/journal.pone.0192640.CrossRefPubMedPubMedCentral

33.

Kuchenbecker U, Chase D, Reichert A, Schiffner-Rohe J, Atwood M. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany. PLoS One. 2018;13:e0197905. https://doi.org/10.1371/journal.pone.0197905.CrossRefPubMedPubMedCentral

34.

Merito M, Giorgi Rossi P, Mantovani J, Curtale F, Borgia P, Guasticchi G. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy. Vaccine. 2007;25:458–65. https://doi.org/10.1016/j.vaccine.2006.08.005.CrossRefPubMed

35.

Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged or = 65 years in the Netherlands. Clin Ther. 2010;32:1517–32. https://doi.org/10.1016/j.clinthera.2010.06.016.CrossRefPubMed

36.

Akin L, Kaya M, Altinel S, Durand L. Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey. Hum Vaccin. 2011;7:441–50.CrossRefPubMedPubMedCentral

37.

Neto JT, de Araujo GTB, Gagliardi A, Pinho A, Durand L, Fonseca M. Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in Sao Paulo State, Brazil. Hum Vaccin. 2011;7:1037–47. https://doi.org/10.4161/hv.7.10.15987.CrossRefPubMedPubMedCentral

38.

Grzesiowski P, Aguiar-Ibanez R, Kobryn A, Durand L, Puig P-E. Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland. Hum Vaccin Immunother. 2012;8:1382–94. https://doi.org/10.4161/hv.21571.CrossRefPubMedPubMedCentral

39.

Kuhlmann A, Theidel U, Pletz MW, von der Schulenburg J-MG. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev. 2012;2:4. https://doi.org/10.1186/2191-1991-2-4.CrossRefPubMedPubMedCentral

40.

Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012;307:804–12. https://doi.org/10.1001/jama.2012.169.CrossRefPubMedPubMedCentral

41.

Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥ 50 years. Vaccine. 2012;30:5437–44. https://doi.org/10.1016/j.vaccine.2012.05.076.CrossRefPubMed

42.

Chen J, O’Brien MA, Yang HK, Grabenstein JD, Dasbach EJ. Cost-effectiveness of pneumococcal vaccines for adults in the United States. Adv Ther. 2014;31:392–409. https://doi.org/10.1007/s12325-014-0115-y.CrossRefPubMedPubMedCentral

43.

Liguori G, Parlato A, Zamparelli AS, Belfiore P, Galle F, Di Onofrio V, et al. Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation. Hum Vaccin Immunother. 2014;10:492–7. https://doi.org/10.4161/hv.26888.CrossRefPubMed

44.

Ordonez JE, Orozco JJ. Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia. BMC Infect Dis. 2014;14:172. https://doi.org/10.1186/1471-2334-14-172.CrossRefPubMedPubMedCentral

45.

de Soarez PC, Sartori AMC, Freitas AC, Nishikawa AM, Novaes HMD. Cost-effectiveness analysis of universal vaccination of adults aged 60 years with 23-valent pneumococcal polysaccharide vaccine versus current practice in Brazil. PLoS One. 2015;10:e0130217. https://doi.org/10.1371/journal.pone.0130217.CrossRefPubMedPubMedCentral

46.

Zhao D, Gai Tobe R, Cui M, He J, Wu B. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. Vaccine. 2016;34:6158–65. https://doi.org/10.1016/j.vaccine.2016.11.003.CrossRefPubMed

47.

Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008. https://doi.org/10.1002/14651858.cd000422.pub2.CrossRefPubMed

48.

Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, Llor C. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis. 2006;43:860–8. https://doi.org/10.1086/507340.CrossRefPubMed

49.

Rodriguez-Barradas MC, Goulet J, Brown S, Goetz MB, Rimland D, Simberkoff MS, et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis. 2008;46:1093–100. https://doi.org/10.1086/529201.CrossRefPubMedPubMedCentral

50.

van Werkhoven CH, Huijts SM, Bolkenbaas M, Grobbee DE, Bonten MJM. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin Infect Dis. 2015;61:1835–8. https://doi.org/10.1093/cid/civ686.CrossRefPubMed

51.

van Werkhoven CH, Huijts SM, Bolkenbaas M. 13-valent pneumococcal conjugate vaccine efficacy is declining with old age: results from an exploratory analysis of the CAPiTAtrial. In: ID-Week: Philadelphia < 2014. Abstract #1099.

52.

Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341–8. https://doi.org/10.1056/NEJMoa035060.CrossRefPubMed

53.

Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013. https://doi.org/10.1002/14651858.cd000422.pub3.CrossRefPubMed

54.

Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180:48–58. https://doi.org/10.1503/cmaj.080734.CrossRefPubMedPubMedCentral

55.

French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355:2106–11.CrossRefPubMed

56.

Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (ppv23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12:e0169368. https://doi.org/10.1371/journal.pone.0169368.CrossRefPubMedPubMedCentral

57.

Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, Hospital-Guardiola I. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014;58:909–17. https://doi.org/10.1093/cid/ciu002.CrossRefPubMed

58.

Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325:1453–60. https://doi.org/10.1056/NEJM199111213252101.CrossRefPubMed

59.

Kraicer-Melamed H, O’Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis. Vaccine. 2016;34:1540–50. https://doi.org/10.1016/j.vaccine.2016.02.024.CrossRefPubMed

60.

Ortqvist A, Hedlund J, Burman LA, Elbel E, Höfer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 1998;351:399–403.CrossRefPubMed

61.

Smith KJ, Zimmerman RK, Lin CJ, Nowalk MP, Ko F-S, McEllistrem MC, Roberts MS. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine. 2008;26:1420–31. https://doi.org/10.1016/j.vaccine.2008.01.007.CrossRefPubMed

62.

Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. 2002;21:303–11.CrossRefPubMed

63.

Knol MJ, Wagenvoort GHJ, Sanders EAM, Elberse K, Vlaminckx BJ, de Melker HE, van der Ende A. Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis. 2015;21:2040–4. https://doi.org/10.3201/eid2111.140780.CrossRefPubMedPubMedCentral

64.

Pletz MW, Ewig S, Rohde G, Schuette H, Rupp J, Welte T, et al. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay. Vaccine. 2016;34:2342–8. https://doi.org/10.1016/j.vaccine.2016.03.052.CrossRefPubMed

65.

Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine. 2009;27:1504–10. https://doi.org/10.1016/j.vaccine.2009.01.013.CrossRefPubMed

66.

Gutiérrez Rodríguez MA, Ordobás Gavín MA, García-Comas L, Sanz Moreno JC, Córdoba Deorador E, Lasheras Carbajo MD, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011. Eurosurveillance. 2014. https://doi.org/10.2807/1560-7917.es2014.19.40.20922.CrossRefPubMed

67.

Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, Andrews NJ. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018;6:42–50. https://doi.org/10.1016/j.eclinm.2018.12.007.CrossRefPubMed

68.

Wright LB, Hughes GJ, Chapman KE, Gorton R, Wilson D. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006–July 2012. Trials Vaccinol. 2013;2:45–8. https://doi.org/10.1016/j.trivac.2013.09.004.CrossRef

69.

Bilcke J, Verelst F, Beutels P. Sponsorship bias in base-case values and uncertainty bounds of health economic evaluations? A systematic review of herpes zoster vaccination. Med Decis Making. 2018;38:730–45. https://doi.org/10.1177/0272989X18776636.CrossRefPubMed

70.

Slotved H-C, Dalby T, Harboe ZB, Valentiner-Branth P, Casadevante VFD, Espenhain L, et al. The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination. Heliyon. 2016;2:e00198. https://doi.org/10.1016/j.heliyon.2016.e00198.CrossRefPubMedPubMedCentral

71.

Southern J, Andrews N, Sandu P, Sheppard CL, Waight PA, Fry NK, et al. Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England. PLoS One. 2018;13:e0195799. https://doi.org/10.1371/journal.pone.0195799.CrossRefPubMedPubMedCentral

72.

Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18:441–51. https://doi.org/10.1016/S1473-3099(18)30052-5.CrossRefPubMed

73.

van Deursen AMM, van Houten MA, Webber C, Patton M, Scott D, Patterson S, et al. The impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in the community acquired pneumonia immunization trial in adults (CAPiTA) study. Clin Infect Dis. 2018;67:42–9. https://doi.org/10.1093/cid/ciy009.CrossRefPubMed

74.

Cafiero-Fonseca ET, Stawasz A, Johnson ST, Sato R, Bloom DE. The full benefits of adult pneumococcal vaccination: a systematic review. PLoS One. 2017;12:e0186903. https://doi.org/10.1371/journal.pone.0186903.CrossRefPubMedPubMedCentral

75.

Pilishvili T, Gierke R, Farley M, Schaffner W, Thomas A, Reingold A, et al. Direct and Indirect impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD) among children and adults in the U.S. Open Forum Infect Dis. 2017;4:S66–7. https://doi.org/10.1093/ofid/ofx162.158.CrossRefPubMedCentral

76.

Vila-Corcoles A, Ochoa-Gondar O. Pneumococcal conjugate vaccination: correlates of protection. Lancet Infect Dis. 2014;14:784–6. https://doi.org/10.1016/S1473-3099(14)70849-7.CrossRefPubMed

77.

Domínguez Á, Ciruela P, Hernández S, García-García JJ, Soldevila N, Izquierdo C, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7–59 months. A matched case-control study. PLoS One. 2017;12:e0183191. https://doi.org/10.1371/journal.pone.0183191.CrossRefPubMedPubMedCentral

78.

Falkenhorst G, Remschmidt C, Harder T, Wichmann O, Glodny S, Hummers-Pradier E, et al. Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016;59:1623–57. https://doi.org/10.1007/s00103-016-2466-9.CrossRefPubMed

Title: Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions
Authors: Marina Treskova
Stefan M. Scholz
Alexander Kuhlmann
Publication date: 01-09-2019
Publisher: Springer International Publishing
Keywords: Pneumococcal Vaccination
Vaccination
Published in: PharmacoEconomics / Issue 9/2019
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-019-00805-5

At a glance: The STEP trials

Springer Medicine

Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2019

Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations

Severity-Adjusted Probability of Being Cost Effective

The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal